Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 13/20 | 0.86 |
| ▸ | MMP2 | P08253 | 3/20 | 0.58 |
| ▸ | MMP13 | P45452 | 3/20 | 0.58 |
| ▸ | MMP9 | P14780 | 2/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291742 | 0.93 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6291750 | 0.85 | ADAM17 (1.00) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6986922 | 0.84 | ADAM17 (0.73) | ADAM17MMP2MMP13MMP9 | |
| SCHEMBL6291772 | 0.80 | ADAM17 (0.91) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6291818 | 0.80 | ADAM17 (1.00) | ADAM17 | |
| SCHEMBL6989061 | 0.78 | ADAM17 (0.59) | ADAM17 | |
| SCHEMBL6295428 | 0.77 | MMP13 (0.86) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6295430 | 0.77 | MMP13 (0.86) | ADAM17MMP2MMP13MMP9MMP3 | |
| SCHEMBL6291727 | 0.76 | ADAM17 (1.00) | ADAM17 | |
| SCHEMBL6296128 | 0.75 | MMP2 (1.00) | ADAM17MMP2MMP13MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322627-A1 | CYCLIC SULFONYL COMPOUNDS AS INHIBITORS OF METALLOPROTEASES | Bristol-Myers Squibb Pharma Company (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002028846-A1 | CYCLIC SULFONYL COMPOUNDS AS INHIBITORS OF METALLOPROTEASES | DUPONT PHARMACEUTICALS COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |